Greg Englehardt’s Post

🌟 Introducing Anorit Medical: Empowering bystander involvement in Cardiac Arrest 🌟 Welcome to Anorit Medical! We are happy to have you with us on this exciting journey! Let us introduce ourselves and share what our company is all about. 🚀 At Anorit Medical, we believe that everyone can be a lifesaver. Our mission is to empower bystanders to provide early ventilation to Cardiac Arrest patients, thus improving their chances of survival and return to a good quality of life. In those critical moments, every second counts, and we want to ensure that anyone, anywhere, can make a difference. Our founding team of three — Andreas, Minik and Sotiria, comes from diverse backgrounds, bringing together expertise from healthcare, design and the medical device industry, enriched by our different cultural perspectives and insights. 👥 Meet Our Founders: - Minik Nørreslet - CTO: A skilled Osteopath with a passion for engineering and a business drive -Sotiria Athanasiadou - CEO: A seasoned medtech professional known for a strong grit and commitment to improving patients' lives - Andreas Konradsen - CPO: An experienced industrial designer with a vision to transforming healthcare with accessible and effective devices We are still at the beginning of our ventures, but we are dedicated to making a real impact and we would love to have you along with us for the ride. Together, we can make a difference to many people's lives! #MeetTheTeam #Startup #HealthcareInnovation #MedTech #Entrepreneurship #HealthcareTechnology #Innovation #StartupCommunity

Here’s Reinhard Krickl, CEO of Phagenesis Ltd, quoting his co-founder Conor Mulrooney:  “What's important is not what your device can do, but what it can do for the end user. So it's not about the features and all the cool technology you’re developing. It's really what's going to net the biggest impact in the hands of the user. What is it going to solve for them?” Reinhard is an engineer turned #medtech entrepreneur who thinks transforming patient care through technology is “the most exciting thing you can do.” Under his leadership, Phagenesis is commercializing a neurostimulation system designed to treat dysphagia—difficulty in swallowing—which affects millions of patients globally, especially after stroke or extensive ventilator use. Here's a sneak peek at Reinhard’s conversation with Scott Nelson: ☘️ Simplify for impact: In medtech, focus less on features that don’t contribute to usability or functionality and more on intuitive design that solves real user needs. Understand your market by engaging stakeholders with an open mind. 🧩 Understand the ecosystem: Know how your tech fits into the clinical workflow. Additionally, structural dynamics, such as regulatory requirements, reimbursement policies, and standard of care procedures, can either hinder or facilitate the adoption of your device. 👁️🗨️ Consistent investor communication is crucial for securing funding. When it comes to pitching, you have to be able to tell an engaging story. Use every opportunity, regardless of the outcome, as a learning experience. Learn more from Reinhard’s experience in medtech [link in comments]. This Medsider episode was brought to you by FastWave Medical, a hot IVL startup in the cardiovascular space. Don’t miss out on their next fundraise (more details in the comments). P.S. - We recently launched Medsider Mentors Volume VI, which is packed with insights and learnings from founders and CEOs of some of the most dynamic medical device and health technology startups in the world. Click the link in the comment section for this latest edition now available exclusively to our premium members.

💵 Sunfox Secures Funding from Venture Catalysts and Others to Scale ECG Device Spandan. Sunfox has raised new funding from Venture Catalysts and other investors to expand its ECG device, Spandan, aiming to revolutionize cardiac monitoring. 💰 Funding Details: - Sunfox has successfully secured funding to support the growth and scaling of its ECG device, Spandan. - The investment round includes contributions from Venture Catalysts and additional investors, highlighting confidence in Sunfox’s technology. 🔬 Product Focus: - The funding will be used to enhance Spandan, Sunfox’s advanced ECG device designed for efficient and accurate cardiac monitoring. - The device aims to provide more accessible and reliable heart health diagnostics, benefiting both healthcare providers and patients. 🚀 Growth and Expansion: - With this investment, Sunfox plans to scale its operations and accelerate the deployment of Spandan in the market. - The company aims to improve the device’s features, expand its user base, and enhance its overall impact on cardiac care. 🌟 Strategic Impact: - The support from Venture Catalysts and other investors reflects the growing interest and potential in innovative health tech solutions. - Sunfox is positioned to advance its mission of transforming cardiac diagnostics with cutting-edge technology. 📈 Future Outlook: - The new funding is expected to propel Sunfox’s growth, allowing it to make significant strides in the medical technology sector. - The company’s efforts will focus on delivering advanced, user-friendly ECG solutions and contributing to improved heart health outcomes. Sunfox’s successful funding round represents a key step in scaling its ECG device, Spandan, and advancing its vision of enhancing cardiac monitoring and care. Sunfox Technologies #Sunfox #ECGDevice #Spandan #HealthTech #Microshots #StartupNews #NewsUpdates

When asked to describe the past 20 years of NeuroNexus, Rio describes the time as "transformative". "Building a company from the ground up involves innovative thinking and a forward-looking vision," he continues. "NeuroNexus has undergone a remarkable evolution over the past 20 years. During the challenging but exciting startup phase, we faced significant uncertainty about the viability of our business. Grant funding played a crucial role in supporting our early efforts. As we grew, we expanded our team and formed successful partnerships with major players like Philips Research." "Creating intellectual property was another milestone that added significant value to our company. This positioned us well for our eventual acquisition by Greatbatch, which elevated our discipline and knowledge as we became a subsidiary of a publicly traded medical device company. The experience of spinning out with Nuvectra, a spinal cord stimulation company, provided us with invaluable exposure to the medtech industry." "Eventually, we came full circle and identified an opportunity to acquire NeuroNexus, transforming it back into a private company. Throughout these transitions, our resilience, grit, and discipline guided us, positioning NeuroNexus today as stronger than ever."

📣 Ready to see the BIGGEST #M2D2IMPACT Pitch-Off in the program’s history? 19 #Startups will join us and program partner FORGE in Lowell and compete for prizes that can help propel their solutions to market and into the hands of patients. We’ll kick off the next few weeks (starting today!) with a little insight into each of the IMPACT startups in Cohort 7. Learn more about them ⬇️ and save your spot at the IMPACT Cycle 7 Pitch-Off on April 10th! Reserve your free tickets with the link in the comments. 🔷 CranioSense In 98% of traumatic brain injuries (#TBI), intracranial pressure is never tested, which leaves patients vulnerable to additional brain damage, comas, seizures and more. CranioSense is ready to change how medical professionals treat this problem. Instead of drilling a hole into the skull, their #NonInvasive device IPASS can measure intracranial pressure in seconds. 🔷 Dialysis-X, Inc Did you know the needles used during #Dialysis treatment can cause fatal complications and hospitalizations of patients? Dialysis-X has a unique, life-saving approach to this problem - a needle-free implant that provides a safer, easier-to-use alternative for patients. 🔷 Emitech, Inc. They have developed a rapid, non-invasive and cost-effective #PointOfCare drug testing device, OpiTest. Their solution will help facilitate drug testing routines with faster, more affordably and with more accuracy. 🔷 INIA Biosciences Their name comes from a genus of river dolphins in South America. Why? The dolphins are known for their use of bio sonar to communicate and at INIA Biosciences, they utilize non-invasive ultrasound with diagnostic testing to treat chronic diseases. They’re harnessing ultrasound bioelectronics to improve the future of healthcare. #MedicalDevice #Biotechnology #PitchCompetition

#fundingalert 💼Company: Atraverse Medical, Inc. 💰Funding: $12.5Million ⚡Round: Seed 👥Investors: Physicians, reputable venture investors, and successful medtech entrepreneurs. Atraverse Medical is a medical device company pioneering next-generation left-heart access technology. The company’s proprietary HOTWIRE™ system, featuring universal sheath compatibility and optimized RF technology, aims to enhance outcomes and streamline workflows for physicians treating cardiovascular disease in millions of patients worldwide. The money will be used by the firm to further its early commercialization plans and increase its R&D activities. Atraverse Medical, led by CEO John Slump, announced that its HOTWIRETM radiofrequency (RF) guidewire has received FDA clearance. Steven Mickelsen , John Slump Read more - https://lnkd.in/gMNTAzFV To share your startup story write us on - contact@startuprise.io #AtraverseMedical #medicaldevicecompany #radiofrequency #commercialization #technology #funding #fundingnews #startup #startupnews #startuprise

“The well-trodden path in medtech doesn’t always have to be the default. It’s possible to put collaboration over competition and develop partnership-driven models where incentives truly are aligned.” Our CEO David Hochman was recently featured in Scott Nelson’s article in MD+DI on the value of taking the less-trodden path. Learn more about Orchestra BioMed’s unique approach for success: #innovation #medtech #PatientFirst

🚀 CroiValve in The Times! 📰 Thrilled to see our medtech startup, CroiValve, featured for revolutionizing heart condition treatment. This is just the start—big things ahead! Check out the article here: https://lnkd.in/eya4GRve #CroiValve #MedTech #MedTechSyndicate #HealthcareInnovation

I love seeing these clips from LSI USA 2024. That conference went by so quickly that I missed too many terrific panels! I appreciate Chris Eso's take in this clip: “If you think about what the world looks like in 10-15-20 years from now from a medical device, it’s going to be all connected. It’s going to be all data generating. It’s going to be how you use that data to get better outcomes longer term.” This is exactly why The Shape Sensing Company is building tools to track surgical devices. Not just for navigation during procedures (which is a huge benefit), but the data associated with the navigation will inform us on what went right, what went wrong, and how to improve patient outcomes in the future. Fiber optic 3D guidance is the only technology that can provide full-length, three-dimensional device location, bending, and torque tracking for any tool used in a procedure. And we're not too far off from the future that Chris talks about being a reality. #patientoutcomes #digitalsurgery #futureofhealthcare #fiberoptics

“You've got to balance the idea that the doctors that first work with you are going to understand that they have technology that isn't complete, that this isn't the final generation. But you need to have developed it in such a way that there is a real path to that final version.” Dan Rose is back on Medsider to share his proven #medtech insights after LimFlow SA’s recent exit to Inari Medical. With 25 years of experience in both startups and industry giants like Medtronic, Dan talks about M&A transactions, engaging with investors while maintaining business autonomy, and the importance of developing your #medicaldevice with the average user in mind. LimFlow’s technology tackles Peripheral Artery Disease (PAD) and Chronic Limb-Threatening Ischemia (CLTI) – conditions where blocked arteries threaten limb viability and may potentially lead to amputation. Instead of trying to open blockages, LimFlow ingeniously reroutes blood flow through adjacent veins, restoring circulation and offering hope to patients who suffer from this disease. Here’s a sneak peek into his interview with Scott Nelson: ⚖️ Vet your potential investors carefully and consider how their involvement will impact your business operations, especially if there are multiple parties involved. Limit their influence on decision-making to maintain flexibility and control over your company's direction. 🥼 In the early development phases, design for the average user to maximize adoption rates. Always iterate towards simplicity and be prepared to pivot accordingly. And don't hold onto complex elements or features simply because they were part of the original plan. 💵 Understanding the reimbursement landscape and how your technology fits into that is crucial to progress your conversations with VCs. Research potential investors to ensure that they have the capacity to invest and that their interests match your company's focus. Click on the link in the comments section to follow Dan’s journey building and exiting LimFlow. This Medsider episode was brought to you by FastWave Medical, a hot IVL startup in the cardiovascular space. Don’t miss out on their next fundraise (more details in the comments). P.S. - We just launched Medsider Mentors Volume V, which is packed with insights and learnings from founders and CEOs of some of the most dynamic medical device and health technology startups in the world. Click the link in the comment section for this latest edition now available exclusively to our premium members.